Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

Core Insights - VolitionRx Limited has announced the completion of validation for its automated Nu.Q® Vet Cancer Test in collaboration with Fujifilm Vet Systems, marking a significant advancement in veterinary diagnostics [1] - The automated test is expected to enhance efficiency in veterinary hospitals, with over 1,700 facilities in Japan already registered to use the test since its launch in July 2024 [1] - The partnership with Fujifilm Vet Systems presents a substantial revenue opportunity for Volition, given the large market of approximately seven million pet dogs in Japan [1] Company Overview - Volition is a multinational epigenetics company focused on developing blood tests for early disease detection, including cancer, with a commitment to improving outcomes for both humans and animals [1] - The company operates research and development activities primarily in Belgium, with additional offices in the U.S. and London [1] - Volition's technology platform demonstrates synergy between human and veterinary diagnostics, utilizing the same automated analyzer platform for both [1] Market Context - Cancer is identified as the leading cause of adult canine deaths, and early detection through the Nu.Q® Vet Cancer Test can significantly improve treatment outcomes [1] - Fujifilm Vet Systems, a subsidiary of Fujifilm Holdings Corporation, is a key player in the Japanese veterinary diagnostics market, providing services to approximately 11,000 veterinary medical facilities [1] - The automated testing capability is expected to meet the increasing demand for rapid and high-throughput diagnostic solutions in veterinary medicine [1]